[VoiceOps] Phase III clinical trials of Kamailio DMQ

Thu Apr 1 15:34:24 EDT 2021

Maybe they should open their eyes instead of doing a double-blind study! 
LOL!

MARY LOU CAREY
BackUP Telecom Consulting
Office: 615-791-9969
Cell: 615-796-1111

On 2021-04-01 02:27 PM, Hiers, David wrote:
> No AI here...  This is classic, small-batch, hand-crafted, free-range,
> organic, gluten-free content.
> 
> 
> David
> 
> 
> -----Original Message-----
> From: VoiceOps <voiceops-bounces at voiceops.org> On Behalf Of Alex 
> Balashov
> Sent: Thursday, April 1, 2021 12:18 PM
> To: Brandon Svec <bsvec at teamonesolutions.com>
> Cc: voiceops at voiceops.org
> Subject: Re: [VoiceOps] Phase III clinical trials of Kamailio DMQ
> 
> Let me make sure I understand your question correctly: it is your
> belief or conjecture that this press release was automatically
> generated by a machine learning system?
> 
> —
> Sent from mobile, with due apologies for brevity and errors.
> 
>> On Apr 1, 2021, at 3:10 PM, Brandon Svec <bsvec at teamonesolutions.com> 
>> wrote:
>> 
>> GPT-3? Happy April Fools Day.
>> 
>> Brandon
>> 
>>> On Mar 31, 2021, at 9:47 PM, Alex Balashov 
>>> <abalashov at evaristesys.com> wrote:
>>> 
>>> For immediate release:
>>> 
>>> GAINESVILLE, Florida (1 April 2021)--Evariste Systems, in partnership
>>> with Posner | Palner Pharmaceuticals, are pleased to announce the
>>> eagerly anticipated start of Phase III clinical trials of Kamailio
>>> DMQ module replication.
>>> 
>>> In this stage of the investigation of the promising replication
>>> scheme, which was developed in record time, DMQ will be tested in a
>>> rigourous, double-blind, controlled CI/CD process for large-scale
>>> efficacy and continually monitored for safety in shorter and longer 
>>> terms.
>>> 
>>> The now-concluded second phase established basic safety and Phase 2b
>>> entailed a dose-finding study for the optimal number of batched
>>> `dmq_usrloc` contacts per kilogram of cloud computing resource.
>>> 
>>> The main cohort of the main sequence of the Phase III trial will
>>> enroll 380 randomly selected, statistically representative Floridian
>>> SIP registrars and
>>> 5700 SIP dialogs, also in the state of Florida. When asked about the
>>> disparity in the number of registrars versus dialogs, Alex Balashov
>>> of Evariste said, "It is reflective of the small number of SIP
>>> registrars in Florida; not to be indelicate, but consider the median 
>>> age of the population."
>>> 
>>> As previously remarked upon in proceedings of the World SIP
>>> Organisation (WSO), the choice of Florida as a venue attracted some
>>> questions. We asked Fred Posner of Posner | Palner about the clinical
>>> background informing this choice of replication study cohort:
>>> 
>>> "Florida is a good place to find eventual consistency failures; the
>>> open climate and reluctance to accept traditional data integrity
>>> science would have sealed the deal, but when people started to drink
>>> bleach here, I saw an opportunity."
>>> 
>>> Evariste and Posner | Palner are aiming for a US Food & Drug
>>> Administration EUA (Emergency Use Authorisation) for DMQ replication
>>> as a prophylactic data redundancy and failover measure to ward off
>>> the development of moderate to severe viral Sonus Haemorrhagic Fever 
>>> symptoms.
>>> 
>>> Phase II studies have painted a promising a picture of the DMQ
>>> architecture's ability to reduce moderate to severe symptoms and
>>> associated 28-day mortality by more than 90%, albeit over a small
>>> sample size and in enterprise patients with known pre-existing
>>> comorbidities such as Session Border Controller and BroadSoft
>>> Multi-System Inflammatory Syndrome.  Phase III trials seek to bolster
>>> quantums of broader efficacy, including efficacy for localised 
>>> outbreaks of small to medium business softswitch.
>>> 
>>> Of the control group, Balashov said, "They will receive a standard
>>> pipe-to-/dev/null placebo protocol, but with identical '200 OK'
>>> confirmation messages. We proudly developed this approach in early
>>> 2020 in consultation with the highest levels of the Trump
>>> presidential administration; it is called TENP, or 'The Emperor's New
>>> Potion.' It is a successor to that administration's previous approved 
>>> placebo protocol, SHTI - Small Hands, Tremendous Initiatives."
>>> 
>>> Despite speculative autism and packet fragmentation claims by Florida
>>> Governor Ron DeSantis, Balashov was quick to provide reassurance
>>> about side effects from DMQ in the Phase III trial.
>>> 
>>> "The incidence of severe allergies to plain-text UDP was within
>>> standard deviation over the mean for all insecure replication, and
>>> there's support for other transports on the way. Anyway, we have a
>>> robust adverse effects reporting system in our issue tracker and
>>> solid surveillance. Don't let partisan politics dissuade you from 
>>> allowing request lines with the KDMQ method."
>>> 
>>> Other industry sources have reported that DMQ is not the only
>>> replication investigation undertaken by Evariste and Posner | Palner,
>>> although it is the only prophylactic suitable for the early infection
>>> development and inflammatory phases of a broad class of SBC-complex
>>> syndromes typically afflicting service providers. A recent IETF
>>> preprint by the same authors has shown high-quality preliminary data
>>> suggesting statistically significant improvement in morbidity
>>> outcomes from Perimeta and Nokia via a later-stage therapeutic 
>>> intervention with a monoclonal, monorepo Github cocktail administered 
>>> intravenously.
>>> 
>>> 
>>> --
>>> Alex Balashov | Principal | Evariste Systems LLC
>>> 
>>> Tel: +1-706-510-6800 / +1-800-250-5920 (toll-free)
>>> Web: http://www.evaristesys.com/, http://www.csrpswitch.com/
>>> _______________________________________________
>>> VoiceOps mailing list
>>> VoiceOps at voiceops.org
>>> https://puck.nether.net/mailman/listinfo/voiceops
> _______________________________________________
> VoiceOps mailing list
> VoiceOps at voiceops.org
> https://puck.nether.net/mailman/listinfo/voiceops
> 
> ----------------------------------------------------------------------
> This message and any attachments are intended only for the use of the
> addressee and may contain information that is privileged and
> confidential. If the reader of the message is not the intended
> recipient or an authorized representative of the intended recipient,
> you are hereby notified that any dissemination of this communication
> is strictly prohibited. If you have received this communication in
> error, notify the sender immediately by return email and delete the
> message and any attachments from your system.
> _______________________________________________
> VoiceOps mailing list
> VoiceOps at voiceops.org
> https://puck.nether.net/mailman/listinfo/voiceops